## Abraham Nudelman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1891041/publications.pdf

Version: 2024-02-01

110 papers 9,535 citations

34 h-index 94 g-index

110 all docs

110 docs citations

110 times ranked

12474 citing authors

#	Article	IF	Citations
1	Dimeric Drugs. Current Medicinal Chemistry, 2022, 29, 2751-2845.	1.2	3
2	An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells. Cancer Chemotherapy and Pharmacology, 2022, , 1.	1.1	0
3	A switch in mechanism of action prevents doxorubicin-mediated cardiac damage. Biochemical Pharmacology, 2021, 185, 114410.	2.0	2
4	Comparison of the tissue distribution and metabolism of AN1284, a potent anti-inflammatory agent, after subcutaneous and oral administration in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 2077-2089.	1.4	1
5	Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer. Pharmaceuticals, 2021, 14, 1244.	1.7	O
6	Cardioprotection by AN-7, a prodrug of the histone deacetylase inhibitor butyric acid: Selective activity in hypoxic cardiomyocytes and cardiofibroblasts. European Journal of Pharmacology, 2020, 882, 173255.	1.7	9
7	Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and $\hat{I}^2$ -YAC transgenic mice. Blood Cells, Molecules, and Diseases, 2019, 79, 102345.	0.6	10
8	Synthesis and Biological Evaluation of Derivatives of Indoline as Highly Potent Antioxidant and Anti-inflammatory Agents. Journal of Medicinal Chemistry, 2018, 61, 4004-4019.	2.9	39
9	AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair. Investigational New Drugs, 2018, 36, 1-9.	1.2	14
10	Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. Journal of Cellular Biochemistry, 2018, 119, 3417-3428.	1.2	15
11	Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 480-486.	0.6	6
12	Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. Investigational New Drugs, 2017, 35, 412-426.	1.2	8
13	Development of GSK's NMR guides – a tool to encourage the use of more sustainable solvents. Green Chemistry, 2016, 18, 3867-3878.	4.6	22
14	Bi-functional prodrugs of 5-aminolevulinic acid and butyric acid increase erythropoiesis in anemic mice in an erythropoietin-independent manner. European Journal of Pharmaceutical Sciences, 2016, 91, 91-97.	1.9	5
15	The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin. PLoS ONE, 2016, 11, e0146115.	1.1	10
16	Acylation or phosphorylation of hydroxyurea unexpectedly takes place on N rather than on O, leading to the formation of amides instead of the expected esters. RSC Advances, 2015, 5, 24038-24043.	1.7	4
17	Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent. Current Topics in Medicinal Chemistry, 2015, 15, 1409-1422.	1.0	19
18	Department of Chemistry, Bar-Ilan University (BIU). Israel Journal of Chemistry, 2014, 54, 1488-1499.	1.0	2

#	Article	IF	CITATIONS
19	Synthesis and in vitro evaluation of anti-inflammatory activity of ester and amine derivatives of indoline in RAW 264.7 and peritoneal macrophages. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2283-2287.	1.0	26
20	A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo. Biochemical Pharmacology, 2014, 88, 158-168.	2.0	17
21	The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts. Cancer Chemotherapy and Pharmacology, 2013, 71, 809-816.	1.1	9
22	Carbamate Derivatives of Indolines as Cholinesterase Inhibitors and Antioxidants for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2012, 55, 10700-10715.	2.9	61
23	Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochemical Pharmacology, 2012, 83, 1602-1612.	2.0	55
24	Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor. PLoS ONE, 2012, 7, e31393.	1.1	22
25	Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death pathways. Investigational New Drugs, 2012, 30, 1028-1038.	1.2	13
26	The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investigational New Drugs, 2012, 30, 130-143.	1.2	31
27	Modulating ALA-PDT efficacy of mutlidrug resistant MCF-7 breast cancer cells using ALA prodrug. Photochemical and Photobiological Sciences, 2011, 10, 1926-1933.	1.6	31
28	Structure–activity relationship studies of 1-(4-chloro-2,5-dimethoxyphenyl)-3-(3-propoxypropyl)thiourea, a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type-1. European Journal of Medicinal Chemistry, 2011, 46, 447-467.	2.6	13
29	NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist. Organometallics, 2010, 29, 2176-2179.	1.1	3,142
30	ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin–DNA adducts. Biochemical Pharmacology, 2010, 79, 339-349.	2.0	22
31	Facile structural elucidation of imidazoles and oxazoles based on NMR spectroscopy and quantum mechanical calculations. Tetrahedron, 2010, 66, 1465-1471.	1.0	12
32	New Anthracenedione Derivatives with Improved Biological Activity by Virtue of Stable Drugâ^'DNA Adduct Formation. Journal of Medicinal Chemistry, 2010, 53, 6851-6866.	2.9	21
33	$\hat{l}^3$ -Aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity. Journal of Medicinal Chemistry, 2009, 52, 3010-3017.	2.9	13
34	BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. European Neuropsychopharmacology, 2009, 19, 1-13.	0.3	32
35	Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clinical and Experimental Metastasis, 2008, 25, 703-716.	1.7	36
36	The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemotherapy and Pharmacology, 2008, 61, 739-749.	1.1	35

#	Article	IF	Citations
37	Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species. Cancer Chemotherapy and Pharmacology, 2008, 62, 471-482.	1.1	19
38	Electrochemical lab on a chip for high-throughput analysis of anticancer drugs efficiency. Nanomedicine: Nanotechnology, Biology, and Medicine, 2008, 4, 121-126.	1.7	30
39	Novel Multifunctional Acyloxyalkyl Ester Prodrugs of 5-Aminolevulinic Acid Display Improved Anticancer Activity Independent and Dependent on Photoactivation. Journal of Medicinal Chemistry, 2008, 51, 7356-7369.	2.9	38
40	A Mutual Prodrug Ester of GABA and Perphenazine Exhibits Antischizophrenic Efficacy with Diminished Extrapyramidal Effects. Journal of Medicinal Chemistry, 2008, 51, 2858-2862.	2.9	24
41	Novel Prodrugs of Tegafur that Display Improved Anticancer Activity and Antiangiogenic Properties. Journal of Medicinal Chemistry, 2008, 51, 314-323.	2.9	21
42	In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas1. Neuro-Oncology, 2007, 9, 82-88.	0.6	47
43	Light-Sensitive Protecting Groups for Amines and Alcohols: The Photosolvolysis of N-Substituted 7-Nitroindolines. Synlett, 2007, 2007, 2405-2409.	1.0	18
44	Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Molecular Cancer Therapeutics, 2007, 6, 1450-1459.	1.9	17
45	AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Letters, 2007, 253, 205-214.	3.2	11
46	The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Letters, 2007, 256, 39-48.	3.2	34
47	De NovoParallel Design, Synthesis and Evaluation of Inhibitors against the Reverse Transcriptase of Human Immunodeficiency Virus Type-1 and Drug-Resistant Variants. Journal of Medicinal Chemistry, 2007, 50, 2370-2384.	2.9	34
48	Hydroxy-1-aminoindans and Derivatives:Â Preparation, Stability, and Reactivity. Journal of Organic Chemistry, 2006, 71, 4130-4140.	1.7	26
49	The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Investigational New Drugs, 2006, 24, 383-392.	1.2	34
50	Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. Journal of Cancer Research and Clinical Oncology, 2006, 132, 673-683.	1.2	27
51	Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death. Cancer Research, 2006, 66, 4863-4871.	0.4	250
52	In vivo andin vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. International Journal of Cancer, 2005, 116, 226-235.	2.3	39
53	Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Molecular Cancer Therapeutics, 2005, 4, 1952-1961.	1.9	74
54	The Role of Intracellularly Released Formaldehyde and Butyric Acid in the Anticancer Activity of Acyloxyalkyl Esters. Journal of Medicinal Chemistry, 2005, 48, 1042-1054.	2.9	51

#	Article	IF	Citations
55	An Improved Synthesis of Hydroxyindoles. Synthesis, 2004, 2004, 3043-3046.	1.2	6
56	Inhibitors of biotin biosynthesis as potential herbicides. Tetrahedron, 2004, 60, 1731-1748.	1.0	23
57	Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells. Cancer Biology and Therapy, 2003, 2, 259-263.	1.5	27
58	Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Molecular Cancer Therapeutics, 2003, 2, 189-98.	1.9	22
59	Sequence specificity of adriamycin-DNA adducts in human tumor cells. Molecular Cancer Therapeutics, 2003, 2, 661-70.	1.9	34
60	A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Molecular Cancer Research, 2003, 1, 903-12.	1.5	11
61	The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood, 2002, 100, 3319-3324.	0.6	70
62	Cinnamic acid derived oxazolinium ions as novel cytotoxic agents. European Journal of Medicinal Chemistry, 2002, 37, 607-616.	2.6	15
63	Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. European Journal of Medicinal Chemistry, 2001, 36, 63-74.	2.6	64
64	From Amino Acids to Fused Chiral Pyrrolidines and Piperidines via the INOC Route. European Journal of Organic Chemistry, 2000, 2000, 645-655.	1.2	14
65	Prodrugs of butyric acid from bench to bedside: Synthetic design, mechanisms of action, and clinical applications. Drug Development Research, 2000, 50, 379-391.	1.4	67
66	Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis. Journal of Cancer Research and Clinical Oncology, 2000, 126, 693-698.	1.2	18
67	Novel Mutual Prodrug of Retinoic and Butyric Acids with Enhanced Anticancer Activity. Journal of Medicinal Chemistry, 2000, 43, 2962-2966.	2.9	41
68	Convenient Syntheses of Î-Aminolevulinic Acid. Synthesis, 1999, 1999, 568-570.	1.2	8
69	IOOC Route to Substituted Chiral Pyrrolidines. Potential Glycosidase Inhibitors. Journal of Organic Chemistry, 1999, 64, 498-506.	1.7	37
70	Ethers. Synthetic Communications, 1999, 29, 1405-1408.	1.1	10
71	Synthetic Communications, 1998, 28, 471-474.	1.1	90
72	The Synthesis of the Vitamers of Biotin. Bioorganic Chemistry, 1998, 26, 157-168.	2.0	11

#	Article	IF	CITATIONS
73	NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities. Journal of Organic Chemistry, 1997, 62, 7512-7515.	1.7	3,270
74	Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. Journal of Cancer Research and Clinical Oncology, 1997, 123, 267-271.	1.2	17
75	Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. Journal of Cancer Research and Clinical Oncology, 1997, 123, 152-160.	1.2	34
76	330, 285-289.	2.1	4
77	Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. Journal of Cancer Research and Clinical Oncology, 1997, 123, 152-160.	1.2	2
78	Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells. Journal of Cancer Research and Clinical Oncology, 1997, 123, 267-271.	1.2	2
79	On the Stabilization of theSyn-Rotamer of Amino Acid Carbamate Derivatives by Hydrogen Bonding. Journal of Organic Chemistry, 1996, 61, 8402-8406.	1.7	66
80	"Vinylogs―and "Acetylenylogs―of β-Adrenergic Agents. Archiv Der Pharmazie, 1996, 329, 125-132.	2.1	5
81	$\hat{l}$ ±-1-Tributyltin-O-2,3-bisacetyl-4,6-ethylidene-glucose as a convenient glycosidation reagent: An efficient synthesis of etoposide. Tetrahedron, 1996, 52, 3049-3056.	1.0	16
82	Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line. International Journal of Cancer, 1994, 56, 906-909.	2.3	50
83	Hypoxic Radiosensitizers: Substituted Styryl Derivatives. Archiv Der Pharmazie, 1994, 327, 619-625.	2.1	4
84	Utilization of L-serine in an oxime olefin cycloaddition route to a functionalized asymmetric pyrrolidine, a selective î±-glucosidase inhibitor. Tetrahedron Letters, 1994, 35, 2397-2400.	0.7	38
85	Approaches to Mutual Prodrugs: Calcium - β-Blockers. Archiv Der Pharmazie, 1993, 326, 907-909.	2.1	4
86	Rapid alteration of c-mycand c-junexpression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Letters, 1993, 328, 225-229.	1.3	49
87	A Convenient Synthesis of Chiral Oxazolidin-2-Ones and Thiazolidin-2-Ones and an Improved Preparation of Triphosgene. Synthetic Communications, 1993, 23, 2839-2844.	1.1	44
88	Novel anticancer prodrugs of butyric acid. 2. Journal of Medicinal Chemistry, 1992, 35, 687-694.	2.9	89
89	Enol oxalacetic acid exists in the Z form in the crystalline state and in solution. Journal of Organic Chemistry, 1992, 57, 7270-7274.	1.7	14
90	Derivatives of butyric acid as potential anti-neoplastic agents. International Journal of Cancer, 1991, 49, 66-72.	2.3	95

#	Article	IF	CITATIONS
91	Archiv Der Pharmazie, 1990, 323, 229-233.	2.1	2
92	Methanolysis of acetylated sugars and glycosides in the presence of tin oxides and alkoxides. Carbohydrate Research, 1988, 177, 21-28.	1.1	15
93	Selective deacetylation of anomeric sugar acetates with tin alkoxides. Carbohydrate Research, 1987, 162, 145-152.	1.1	73
94	Studies in ranitidine chemistry: an unusual oxygen .fwdarw. nitrogen methyl migration. Journal of Organic Chemistry, 1986, 51, 730-732.	1.7	11
95	Studies in sugar chemistry. 2. A simple method for O-deacylation of polyacylated sugars. Journal of Organic Chemistry, 1986, 51, 727-730.	1.7	109
96	Regioselective heterogeneous O-deacylation of polyacylated sugars. Carbohydrate Research, 1986, 153, 162-167.	1.1	26
97	Organotin nucleophiles. 6. Palladium-catalyzed allylic etherification with tin alkoxides. Journal of Organic Chemistry, 1985, 50, 3558-3566.	1.7	87
98	A novel method for stereoselective glucuronidation. Journal of Organic Chemistry, 1984, 49, 4988-4993.	1.7	63
99	Rearrangements of penicillin sulfoxides. 2. Spectral data and x-ray crystallography of the novel imidazo[5,1-c][1,4]thiazine ring system. Journal of Organic Chemistry, 1981, 46, 3026-3029.	1.7	10
100	Semisynthetic cephalosporins. III. Synthesis and structure activity relationships of novel orally active 7-[4-hydroxy-3-(substituted methyl)phenyl]-acetamido-3-cephem-4-carboxylic acids Journal of Antibiotics, 1980, 33, 76-82.	1.0	2
101	The Chemistry of Optically Active Sulfur Compounds-Part IV. Phosphorous and Sulfur and the Related Elements, 1980, 9, 1-79.	0.2	11
102	Rearrangements of penicillin sulfoxides. 1. Journal of Organic Chemistry, 1977, 42, 2887-2890.	1.7	6
103	THE CHEMISTRY OF OPTICALLY ACTIVE SULFUR COMPOUNDS PART III. Phosphorous and Sulfur and the Related Elements, 1976, 2, 51-94.	0.2	13
104	Water-Soluble Derivatives of 3-Oxy-substituted 1,4-Benzodiazepines. Journal of Pharmaceutical Sciences, 1974, 63, 1880-1885.	1.6	22
105	Stereochemistry of sulfur compounds. II. New reactions at chiral sulfur that complete the first monoligostatic stereochemical reaction cycle. Journal of the American Chemical Society, 1972, 94, 4684-4691.	6.6	33
106	Stereochemical reaction cycle with chiral phosphorus. Journal of Organic Chemistry, 1971, 36, 335-337.	1.7	22
107	Enthalpies of transfer of transition states in the Menshutkin reaction from a polar protic to a dipolar aprotic solvent. Journal of Organic Chemistry, 1971, 36, 1792-1795.	1.7	48
108	Unusual condensation-ring closure reaction [forming cyclopropyl sulfoxides]. Journal of Organic Chemistry, 1969, 34, 3659-3661.	1.7	5

#	Article	IF	CITATIONS
109	The stereochemical course of ester-amide interchange leading to optically active phosphinic and sulfinic amides. Journal of the American Chemical Society, 1968, 90, 3869-3870.	6.6	49
110	Sulfinic acids and their derivatives. Stereochemistry and chiroptical properties., 0,, 35-85.		3